174 related articles for article (PubMed ID: 30336216)
1. Pretransplant angiotensin II type 1-receptor antibodies point to an increase in renal graft sub-intimal fibrosis in living- donor kidney transplant recipients.
González-Almada A; Arreola-Guerra JM; López-Sánchez JA; Cuevas E; Vilatoba M; Contreras AG; Morales-Buenrostro LE; Alberu J; Uribe-Uribe NO
Transpl Immunol; 2019 Jun; 54():1-8. PubMed ID: 30336216
[TBL] [Abstract][Full Text] [Related]
2. Pretransplant angiotensin II type 1-receptor antibodies are a risk factor for earlier detection of de novo HLA donor-specific antibodies.
Cuevas E; Arreola-Guerra JM; Hernández-Méndez EA; Salcedo I; Castelán N; Uribe-Uribe NO; Vilatobá M; Contreras-Saldívar AG; Sánchez-Cedillo AI; Ramírez JB; de Rungs D; Granados J; Morales-Buenrostro LE; Alberú J
Nephrol Dial Transplant; 2016 Oct; 31(10):1738-45. PubMed ID: 27220757
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of therapeutic plasma exchange on angiotensin II type-1 receptor antibodies on two kidney transplant recipients.
Yamada C; Huang Y; Norman S; Naik A; Moussa O; Samaniego M; Cooling L
J Clin Apher; 2018 Dec; 33(6):673-677. PubMed ID: 30321467
[TBL] [Abstract][Full Text] [Related]
4. The Influence of Antibodies against Angiotensin II Type-1 Receptor on the Outcome of Kidney Transplantation: A Single-Center Retrospective Study.
Filiopoulos V; Vittoraki A; Vallianou K; Bellos I; Markaki P; Liapis G; Marinaki S; Iniotaki A; Boletis IN
J Clin Med; 2023 Apr; 12(9):. PubMed ID: 37176553
[TBL] [Abstract][Full Text] [Related]
5. Non-HLA agonistic anti-angiotensin II type 1 receptor antibodies induce a distinctive phenotype of antibody-mediated rejection in kidney transplant recipients.
Lefaucheur C; Viglietti D; Bouatou Y; Philippe A; Pievani D; Aubert O; Duong Van Huyen JP; Taupin JL; Glotz D; Legendre C; Loupy A; Halloran PF; Dragun D
Kidney Int; 2019 Jul; 96(1):189-201. PubMed ID: 31005275
[TBL] [Abstract][Full Text] [Related]
6. Pre-transplant angiotensin II type 1 receptor antibodies: A risk factor for decreased kidney graft function in the early post-transplant period?
Hernández-Méndez EA; Arreola-Guerra JM; Morales-Buenrostro LE; Ramírez JB; Calleja S; Castelán N; Salcedo I; Vilatobá M; Contreras AG; Gabilondo B; Granados J; Alberú J
Clin Transpl; 2013; ():343-50. PubMed ID: 25095527
[TBL] [Abstract][Full Text] [Related]
7. ARHGDIB and AT1R autoantibodies are differentially related to the development and presence of chronic antibody-mediated rejection and fibrosis in kidney allografts.
Betjes MGH; Sablik KA; Litjens NHR; Otten HG; de Weerd AE
Hum Immunol; 2021 Feb; 82(2):89-96. PubMed ID: 33358038
[TBL] [Abstract][Full Text] [Related]
8. Histopathologic changes in anti-angiotensin II type 1 receptor antibody-positive kidney transplant recipients with acute rejection and no donor specific HLA antibodies.
Lim MA; Palmer M; Trofe-Clark J; Bloom RD; Jackson A; Philogene MC; Kamoun M
Hum Immunol; 2017 Apr; 78(4):350-356. PubMed ID: 28284829
[TBL] [Abstract][Full Text] [Related]
9. Pre-transplant angiotensin II type 1receptor antibodies: a risk factor for decreased kidney graft function in the early post-transplant period?
Hernández-Méndez EA; Arreola-Guerra JM; Morales-Buenrostro LE; Ramírez JB; Calleja S; Castelán N; Salcedo I; Vilatobá M; Contreras AG; Gabilondo B; Granados J; Alberú J
Rev Invest Clin; 2014; 66(3):218-24. PubMed ID: 25695237
[TBL] [Abstract][Full Text] [Related]
10. Pre-Transplant Angiotensin II Type 1 Receptor Antibodies and Anti-Endothelial Cell Antibodies Predict Graft Function and Allograft Rejection in a Low-Risk Kidney Transplantation Setting.
Yu S; Huh HJ; Lee KW; Park JB; Kim SJ; Huh W; Jang HR; Kwon GY; Moon HH; Kang ES
Ann Lab Med; 2020 Sep; 40(5):398-408. PubMed ID: 32311853
[TBL] [Abstract][Full Text] [Related]
11. Assessing the potential of angiotensin II type 1 receptor and donor specific anti-endothelial cell antibodies to predict long-term kidney graft outcome.
Pinelli DF; Friedewald JJ; Haarberg KMK; Radhakrishnan SL; Zitzner JR; Hanshew WE; Tambur AR
Hum Immunol; 2017; 78(5-6):421-427. PubMed ID: 28372986
[TBL] [Abstract][Full Text] [Related]
12. Donor-Specific Anti-Human Leukocyte Antigens Antibodies, Acute Rejection, Renal Function, and Histology in Kidney Transplant Recipients Receiving Tacrolimus and Everolimus.
Ferreira A; Felipe C; Cristelli M; Viana L; Basso G; Stopa S; Mansur J; Ivani M; Bessa A; Ruppel P; Aguiar W; Campos E; Gerbase-DeLima M; Proença H; Tedesco-Silva H; Medina-Pestana J
Am J Nephrol; 2017; 45(6):497-508. PubMed ID: 28511172
[TBL] [Abstract][Full Text] [Related]
13. Pathologic features of antibody-mediated rejection in renal allografts: an expanding spectrum.
Haas M
Curr Opin Nephrol Hypertens; 2012 May; 21(3):264-71. PubMed ID: 22388553
[TBL] [Abstract][Full Text] [Related]
14. Deleterious effect of anti-angiotensin II type 1 receptor antibodies detected pretransplant on kidney graft outcomes is both proper and synergistic with donor-specific anti-HLA antibodies.
Malheiro J; Tafulo S; Dias L; Martins S; Fonseca I; Beirão I; Castro-Henriques A; Cabrita A
Nephrology (Carlton); 2019 Mar; 24(3):347-356. PubMed ID: 29451342
[TBL] [Abstract][Full Text] [Related]
15. Anti-Angiotensin II Type 1 Receptor and Anti-Endothelial Cell Antibodies: A Cross-Sectional Analysis of Pathological Findings in Allograft Biopsies.
Philogene MC; Bagnasco S; Kraus ES; Montgomery RA; Dragun D; Leffell MS; Zachary AA; Jackson AM
Transplantation; 2017 Mar; 101(3):608-615. PubMed ID: 27222934
[TBL] [Abstract][Full Text] [Related]
16. Circulating donor-specific anti-HLA antibodies are a major factor in premature and accelerated allograft fibrosis.
Gosset C; Viglietti D; Rabant M; Vérine J; Aubert O; Glotz D; Legendre C; Taupin JL; Duong Van-Huyen JP; Loupy A; Lefaucheur C
Kidney Int; 2017 Sep; 92(3):729-742. PubMed ID: 28554738
[TBL] [Abstract][Full Text] [Related]
17. The influence of non-HLA antibodies directed against angiotensin II type 1 receptor (AT1R) on early renal transplant outcomes.
Banasik M; Boratyńska M; Kościelska-Kasprzak K; Kamińska D; Bartoszek D; Zabińska M; Myszka M; Zmonarski S; Protasiewicz M; Nowakowska B; Hałoń A; Chudoba P; Klinger M
Transpl Int; 2014 Oct; 27(10):1029-38. PubMed ID: 24909812
[TBL] [Abstract][Full Text] [Related]
18. Differences in pathologic features and graft outcomes in antibody-mediated rejection of renal allografts due to persistent/recurrent versus de novo donor-specific antibodies.
Haas M; Mirocha J; Reinsmoen NL; Vo AA; Choi J; Kahwaji JM; Peng A; Villicana R; Jordan SC
Kidney Int; 2017 Mar; 91(3):729-737. PubMed ID: 28104301
[TBL] [Abstract][Full Text] [Related]
19. Predictors of renal transplant histology at three months.
Kuypers DR; Chapman JR; O'Connell PJ; Allen RD; Nankivell BJ
Transplantation; 1999 May; 67(9):1222-30. PubMed ID: 10342313
[TBL] [Abstract][Full Text] [Related]
20. Investigation of Serum Angiotensin II Type 1 Receptor Antibodies at the Time of Renal Allograft Rejection.
Lee H; Kim JI; Moon IS; Chung BH; Yang CW; Kim Y; Han K; Oh EJ
Ann Lab Med; 2015 May; 35(3):314-20. PubMed ID: 25932439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
